Sarepta gets path forward for muscular dystrophy drug By: CNBC.com News April 21, 2014 at 06:55 AM EDT Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy. Read More >> Related Stocks: Gsk Plc ADR Sarepta Therapeutics